FINEARTS-HF Trial: Finerenone Offers Significant Benefits for HF Patients Following Recent Worsening Events Dr. Prem Aggarwal1 Oct 2024 6:00 AM ISTUSA: The FINEARTS-HF trial revealed that the benefit-risk profile of finerenone (Kerendia) for heart failure with mildly reduced or preserved ejection...
Triple Combo therapy not likely to benefit heart failure patients with preserved HF: Circulation Medha Baranwal2 Jun 2022 11:00 AM ISTUSA: The combined benefits of an angiotensin receptor-neprilysin inhibitor (ARNI), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose...
Finarone reduces CV and kidney outcomes in diabetics with CKD: Fidelity MD Bureau18 April 2022 9:00 AM ISTType 2 diabetes is the leading cause of chronic kidney disease (CKD) worldwide. International guidelines for the management of CKD in patients with...
Understanding the role of MRAs in management of heart failure with Cardiologist Dr Rajeev Agarwala Dr. Nandita Mohan11 Jan 2022 11:00 AM ISTDesignated as an emerging epidemic in 1997, Heart failure is still a major clinical and public health concern. Many medicines previously used have...
What ESC 2021 guidelines say about use of Mineralocorticoid Receptor Antagonist (MRA) in HFrEF? Dr. Prem Aggarwal18 Nov 2021 11:57 AM ISTThe European Society of Cardiology (ESC) has recently issued guidelines to include Mineralocorticoid Receptor Antagonist (MRA) besides ACE-I and...
MRA Strongly Recommended in Treatment of Heart Failure with Reduced Ejection Fraction: 2021 ESC Guidelines Medical Dialogues Bureau17 Nov 2021 12:45 PM ISTPharmacotherapy is the cornerstone of treatment for Heart Failure with Reduced Ejection Fraction (HFrEF) and should be implemented before considering...
Eplerenone reduces urinary Albumin creatinine ratio in diabetics at high risk of CVD: Study Dr. Shravani Dali18 Oct 2021 9:00 AM ISTEplerenone improves Albumin Excretion in type 2 diabetes (T2D) With Acceptable Safety, suggests a study published in the Diabetes and Metabolism.As...
Dapagliflozin reduces risk for hyperkalemia in HFrEF patients treated with MRAs: Study Dr. Shravani Dali20 Aug 2021 9:00 AM ISTDapagliflozin Reduces Hyperkalemia Risk in Heart Failure and reduced ejection fraction (HFrEF) in patients treated with mineralocorticoid receptor...
Testing for Primary Aldosteronism is low among U.S Veterans: Study MD Bureau22 Jan 2021 6:15 PM ISTIn a recent study, Jordana B. Cohen, M.D., MSCE, and colleagues have reported low adherence to guideline-recommended practices for primary...
